Intralesional acyclovir versus intralesional Hepatitis-B vaccine in treatment of resistant plantar warts: a randomized controlled trial

Treating plantar warts is still a challenging problem with a long list of diverse treatment options that none of them seems to be definitive. To evaluate the effectiveness of intralesional acyclovir versus intralesional Hepatitis-B vaccine (HBV) in treatment of multiple resistant plantar warts. Fort...

Full description

Saved in:
Bibliographic Details
Published in:Archives of Dermatological Research 2024-06, Vol.316 (6), p.325, Article 325
Main Authors: Gharib, Khalid, Taha, Aya, Elradi, Mona
Format: Article
Language:English
Subjects:
Acyclovir
Acyclovir - administration & dosage
Acyclovir - adverse effects
Adolescent
Adult
Antiviral Agents - administration & dosage
Antiviral Agents - therapeutic use
Antiviral drugs
Dermatology
Female
Hepatitis
Hepatitis B Vaccines - administration & dosage
Humans
Injections, Intralesional
Male
Medicine
Medicine & Public Health
Middle Aged
Original Paper
Treatment Outcome
Vaccines
Warts
Warts - drug therapy
Warts - therapy
Young Adult
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Treating plantar warts is still a challenging problem with a long list of diverse treatment options that none of them seems to be definitive. To evaluate the effectiveness of intralesional acyclovir versus intralesional Hepatitis-B vaccine (HBV) in treatment of multiple resistant plantar warts. Forty-eight patients with resistant plantar warts completed the study with no dropouts. They were randomized into 3 groups; group(A) receiving intralesional HBV, group (B) receiving intralesional acyclovir and group (C) receiving intralesional saline as a control group over 5 biweekly sessions or until wart clearance. Clinical outcome was assessed through sequential digital lesion photographing upon each visit. Treatment related adverse reactions were recorded. 43.8%, 37.5% & 18.7% of Groups A, B &C respectively showed a complete response. pain was obvious in 100% and 56.3% of cases receiving intralesional acyclovir and HBV respectively. Up to the 6 month follow up period, none of the complete responders in all groups returned with a recurrence. Both acyclovir and HBV showed comparable efficacy and seem to be promising options for treating plantar warts being safe, affordable, and theoretically safe in immunocompromised cases.
ISSN:1432-069X
0340-3696
1432-069X
DOI:10.1007/s00403-024-03001-4